Shaomeng Wang, PhD
Warner-Lambert/Parke-Davis Professor of Medicine
Medical Director
Internal Medicine
Professor of Internal Medicine
Professor of Pharmacology
Medical School and Professor of Medicinal Chemistry
College of Pharmacy
[email protected]
Available to mentor
Shaomeng Wang, PhD
Professor
Manage Your Profile
Center Memberships
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberRogel Cancer Center
Recent Publications
-
Leng L, Huang L, Tu W, Jiang W, Rej RK, Allu SR, Wang Y, Wang M, Tošović J, Wang M, Wen B, Sun D, Wang S. J Med Chem, 2026 Jun 23;Journal ArticleDiscovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.
DOI:10.1021/acs.jmedchem.6c01093 PMID: 42334193 -
Corradini S, Maksimos M, Azab F, Arsalani S, Nwarunma E, Watt G, Soutar R, Powell M, Henderson R, Travers J, Chen Z, Wang S, Azab AK, Williams MTS. Leukemia, 2026 Jun 16;Journal ArticleTargeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity.
DOI:10.1038/s41375-026-03004-2 PMID: 42303771 -
Kandarpa M, Peterson LF, Potu H, Ramappan M, Liu Y, Polk A, Wang S, Talpaz M. Leukemia, 2026 Apr 15;Journal ArticleActivity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.
DOI:10.1038/s41375-026-02957-8 PMID: 41986621 -
Wu D, Zhou H, Bai L, Acharyya RK, Metwally H, McEachern D, Wang M, Tošović J, Rej RK, Wang M, Wen B, Sun D, Wang S. Journal of Medicinal Chemistry, 2026 Apr 9; 69 (7): 8364 - 8387.Journal ArticleDiscovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
DOI:10.1021/acs.jmedchem.5c03767 PMID: 41871272 -
Ng HL, Glaser TL, Zhu J, Robinson ME, Cosgun KN, Malysheva V, Deniz O, Crump NT, Helian K, Innes AJ, Burt R, Sun L, John G, Zhou H, Kaneshige A, Bai L, Wang S, Spivakov M, Mueschen M, Feldhahn N. Advanced Science, 2026 Jan 1;Journal ArticleBCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs
DOI:10.1002/advs.202517231 -
Baars B, Orive-Ramos A, Emmett MJ, Gaire B, Desaunay M, Kou Z, Li G, Adamopoulos C, Aaronson SA, Wang S, Sellers WR, Martin T, Gavathiotis E, Poulikakos PI. Molecular Cancer Research, 2026 Jan 1; 24 (1): 60 - 71.Journal ArticleRAS Mutation–Specific Responses to Paralog-and State-Selective RAS Inhibitors
DOI:10.1158/1541-7786.MCR-25-0319 PMID: 41091575 -
Chen Z, Dhruv H, Zhang X, Rej RK, Bai L, McEachern D, Kirchhoff P, Nagilla R, Jolivette LJ, Rice CT, Orth P, Strickland CO, Priestley ES, Mohammad HP, Wang M, Wen B, Sun D, Sui Z, Wang S. Nature Communications, 2025 Dec 1; 16 (1):Journal ArticleDevelopment of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
DOI:10.1038/s41467-025-58431-z PMID: 40312344 -
Talpaz M, Kandarpa M, Peterson L, Potu H, Ramappan M, Liu Y, Polk A, Wang S. 2025 Nov 13; Research Square,PreprintActivity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX models
DOI:10.21203/rs.3.rs-7982024/v1
Featured News & Stories
Health Lab
Researchers find a targeted approach to shut down prostate cancer growth
Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling.
Health Lab
Interplay between key proteins could serve as a target for cancer treatment
University of Michigan researchers have identified that the balance between two proteins—STAT3 and STAT5—is important for making tumors vulnerable to immune checkpoint therapy, and targeting STAT3 degradation is a potential novel cancer immunotherapy strategy.
